Credit Rating Update
Balaji Amines Q1 FY27 Results: Revenue at ₹461 Crore, PAT Rises to ₹78 Crore
NSE
BALAMINES
BSE
530999
- Balaji Amines Limited reported a healthy Q1 FY27 performance with consolidated revenue of ₹461 crore, EBITDA of ₹121 crore, and net profit of ₹78 crore. The quarter also marked the commissioning of India’s first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant, while multiple expansion projects remained on track
PRICE-SENSITIVE TRIGGER
Event: Balaji Amines announced its unaudited financial results for the quarter ended June 30, 2026.
Type: Quarterly Financial Results
Impact: Positive
Immediate Effect: The company delivered improved revenue, profitability, and operating margins while advancing strategic expansion projects that are expected to support future growth.
Metrics:
Financial Metrics:
- Revenue: ₹461 crore (vs ₹367 crore YoY | ₹403 crore QoQ)
- EBITDA: ₹121 crore (vs ₹64 crore YoY | ₹102 crore QoQ)
- EBITDA Margin: 26% (vs 17% YoY | 25% QoQ)
- PAT: ₹78 crore (vs ₹37 crore YoY | ₹65 crore QoQ)
- PAT Margin: 17% (vs 10% YoY | 16% QoQ)
- Cash PAT: ₹97 crore (vs ₹51 crore YoY | ₹81 crore QoQ)
- Cash PAT Margin: 20%
- Sales Volume: 21,587 MT (vs 27,570 MT YoY)
Segment Performance:
- Amines: 6,248.57 MT
- Amines Derivatives: 8,205.11 MT
- Specialty Chemicals: 7,132.92 MT
Highlight:
- EBITDA nearly doubled year-on-year to ₹121 crore, while EBITDA margin expanded sharply to 26%, reflecting stronger operating efficiency and improved business conditions.
What Happened ?
Balaji Amines delivered a strong operational performance during Q1 FY27, supported by stable commodity prices, consistent demand across key end-user industries, and improved operating efficiencies. The company also achieved a major strategic milestone by commissioning India’s first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant and continued executing multiple specialty chemicals expansion projects.
key details
Operations & Growth Initiatives
- Consolidated revenue increased to ₹461 crore during Q1 FY27.
- EBITDA improved to ₹121 crore with margins expanding to 26%.
- The company remains a zero-debt entity on a standalone basis.
- India’s first commercial-scale 100,000 TPA DME plant was successfully commissioned.
- The DME project marks Balaji Amines’ entry into alternate fuel applications, including LPG blending and aerosol propellants.
- N-Methyl Morpholine (NMM) and Acetonitrile (ACN) expansion projects are scheduled for commissioning during FY27.
- Balaji Speciality Chemicals continues executing its ₹750 crore phased expansion programme.
- Brownfield and greenfield specialty chemicals projects, including HCN, Sodium Cyanide, EDTA, and downstream EDA derivatives, remain on schedule for commissioning during FY27.
Note:
The ongoing expansion programme is aimed at strengthening the company’s specialty chemicals portfolio while reducing India’s dependence on imports of critical chemical intermediates
Risk Analysis
Summary:
While the company reported strong financial performance, execution of multiple expansion projects and demand across key end-user industries remain important factors for sustaining future growth.
Key Risks:
- Lower sales volumes compared with the previous year despite higher revenue.
- Timely execution of large specialty chemicals expansion projects is critical.
- Demand from pharmaceutical, agrochemical, alternate fuel, and EV battery sectors will influence future growth.
- Geopolitical uncertainties, including the West Asia crisis, could affect operating conditions.
Worst Case:
- Delays in project commissioning or weaker industrial demand could slow revenue growth and impact profitability despite the company’s expanding product portfolio.
Risk Level: Medium
Company Commentary
- Management reported a strong start to FY27 with healthy operational and financial performance.
- Successful commissioning of India’s first commercial-scale DME plant marks an important strategic milestone.
- Expansion projects including NMM, ACN, and Balaji Speciality Chemicals are progressing as planned.
- The company expects healthy demand, ongoing capacity additions, and disciplined execution to support sustainable long-term growth.
- Management remains focused on expanding its presence in high-value specialty chemicals and electronic-grade products.
Official Exchange Filing: Balaji Amines Limited
